Quick Answer
REGENXBIO Inc. reported Revenue (ASC 606) of $170.44 million for fiscal year 2025.
REGENXBIO Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $170.44M | +104.5% |
| 2024 | $83.33M | -7.7% |
| 2023 | $90.24M | -19.9% |
| 2022 | $112.72M | -76.0% |
| 2021 | $470.35M | +204.3% |
| 2020 | $154.57M | +338.7% |
| 2019 | $35.23M | -83.9% |
| 2018 | $218.50M | +2002.4% |
| 2017 | $10.39M | +126.5% |
| 2016 | $4.59M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.73M | +22.9% | +39.2% |
| June 30, 2025 | $21.36M | -4.2% | -76.0% |
| March 31, 2025 | $89.01M | +469.8% | +267.9% |
| September 30, 2024 | $24.20M | -16.3% | +8.5% |
| June 30, 2024 | $22.30M | +11.6% | +42.7% |
| March 31, 2024 | $15.62M | -18.4% | -46.0% |
| September 30, 2023 | $28.91M | +9.1% | +44.7% |
| June 30, 2023 | $19.98M | -38.8% | +4.4% |
- REGENXBIO Inc. showed an increase of +104.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, REGENXBIO Inc.’s revenue (asc 606) has grown by 3614.1% (from $4.59 million to $170.44 million).
- The most recent figure is from REGENXBIO Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: